Cargando…

Prevalence of treated patients with Alzheimer’s disease: current trends and COVID-19 impact

BACKGROUND: There are few updated studies on the prevalence and management of Alzheimer’s disease (AD), which could be underdiagnosed or undertreated. The COVID-19 pandemic may have worsened the deficiencies in the diagnosis and treatment of these patients. Electronic medical records (EMR) offer an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Olazarán, Javier, Carnero-Pardo, Cristóbal, Fortea, Juan, Sánchez-Juan, Pascual, García-Ribas, Guillermo, Viñuela, Félix, Martínez-Lage, Pablo, Boada, Mercè
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401753/ https://www.ncbi.nlm.nih.gov/pubmed/37537656 http://dx.doi.org/10.1186/s13195-023-01271-0

Ejemplares similares

Utility of the Mini-Cog for Detection of Cognitive Impairment in Primary Care: Data from Two Spanish Studies
por: Carnero-Pardo, Cristóbal, et al.
Publicado: (2013)

Attitudes of Neurologists Toward the Use of Biomarkers in the Diagnosis of Early Alzheimer’s Disease
por: Fortea, Juan, et al.
Publicado: (2023)

Efectividad del Mini-Mental en la detección del deterioro cognitivo en Atención Primaria
por: Carnero Pardo, Cristóbal, et al.
Publicado: (2013)

The MAPT H1 Haplotype Is a Risk Factor for Alzheimer’s Disease in APOE ε4 Non-carriers
por: Sánchez-Juan, Pascual, et al.
Publicado: (2019)

Feasibility, safety, and tolerability of two modalities of plasma exchange with albumin replacement to treat elderly patients with Alzheimer's disease in the AMBAR study
por: Boada, Mercè, et al.
Publicado: (2022)

Effective diagnosis of Alzheimer’s disease by means of large margin-based methodology
por: Chaves, Rosa, et al.
Publicado: (2012)

Alzheimer's Disease with Vascular Component: A Distinct Clinical Entity?
por: Olazarán, Javier, et al.
Publicado: (2012)

Burnout among neurologists caring for patients with cognitive disorders in Spain
por: Fortea, Juan, et al.
Publicado: (2023)

Neuropsychological, neuropsychiatric, and quality‐of‐life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study
por: Boada, Mercè, et al.
Publicado: (2021)

Current trends in access to treatment for hepatitis B in immigrants vs non-immigrants
por: Miquel, Mireia, et al.
Publicado: (2020)

A Review on Tramiprosate (Homotaurine) in Alzheimer's Disease and Other Neurocognitive Disorders
por: Manzano, Sagrario, et al.
Publicado: (2020)

Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: from current to future challenges
por: Cano, Amanda, et al.
Publicado: (2021)

Awareness of Diagnosis in Persons with Early-Stage Alzheimer’s Disease: An Observational Study in Spain
por: Villarejo-Galende, Alberto, et al.
Publicado: (2022)

Quality of Life and the Experience of Living with Early-Stage Alzheimer’s Disease
por: Villarejo-Galende, Alberto, et al.
Publicado: (2022)

Distinctive Oculomotor Behaviors in Alzheimer's Disease and Frontotemporal Dementia
por: Lage, Carmen, et al.
Publicado: (2021)

A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study
por: Boada, Mercè, et al.
Publicado: (2020)

Current Understanding of the Physiopathology, Diagnosis and Therapeutic Approach to Alzheimer’s Disease
por: García-Morales, Victoria, et al.
Publicado: (2021)

Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer’s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach
por: Morató, Xavier, et al.
Publicado: (2022)

Quantifying Knowledge of Alzheimer’s Disease: An Analysis of the Psychometric Properties of the Alzheimer’s Disease Knowledge Scale
por: Garcia-Ribas, Guillermo, et al.
Publicado: (2021)

Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline
por: Pascual-Lucas, María, et al.
Publicado: (2023)

Reliable Measurements of the β-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD
por: Pesini, Pedro, et al.
Publicado: (2012)

Epilepsy in Down Syndrome: A Highly Prevalent Comorbidity
por: Altuna, Miren, et al.
Publicado: (2021)

Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer’s disease
por: Sogorb-Esteve, Aitana, et al.
Publicado: (2016)

Mechanisms Involved in Epileptogenesis in Alzheimer’s Disease and Their Therapeutic Implications
por: Altuna, Miren, et al.
Publicado: (2022)

Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer’s Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial
por: Boada, Mercè, et al.
Publicado: (2017)

Long runs of homozygosity are associated with Alzheimer’s disease
por: Moreno-Grau, Sonia, et al.
Publicado: (2021)

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
por: Dekker, Alain D., et al.
Publicado: (2017)

Rare Variants in Calcium Homeostasis Modulator 1 (CALHM1) Found in Early Onset Alzheimer’s Disease Patients Alter Calcium Homeostasis
por: Rubio-Moscardo, Fanny, et al.
Publicado: (2013)

Assessment of a Potential Synergistic Effect of Souvenaid(®) in Mild Alzheimer’s Disease Patients on Treatment with Acetylcholinesterase Inhibitors: An Observational, Non-Interventional Study
por: Viñuela, Félix, et al.
Publicado: (2021)

Exosomes-Based Nanomedicine for Neurodegenerative Diseases: Current Insights and Future Challenges
por: Cano, Amanda, et al.
Publicado: (2023)

Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer’s Disease
por: Perea, Juan R., et al.
Publicado: (2018)

Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress
por: Boada, Mercè, et al.
Publicado: (2019)

Establishing In-House Cutoffs of CSF Alzheimer’s Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort
por: Orellana, Adelina, et al.
Publicado: (2022)

Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria
por: Triviño-Ibáñez, Eva María, et al.
Publicado: (2019)

Increased Albumin Oxidation in Cerebrospinal Fluid and Plasma from Alzheimer’s Disease Patients
por: Costa, Montserrat, et al.
Publicado: (2018)

Kestrel-Prey Dynamic in a Mediterranean Region: The Effect of Generalist Predation and Climatic Factors
por: Fargallo, Juan A., et al.
Publicado: (2009)

Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
por: Pardo-Moreno, Teresa, et al.
Publicado: (2022)

El salario en la crisis económica
por: Olazaran Salinas, Luis Guillermo
Publicado: (1995)

Is the Cerebellum the Optimal Reference Region for Intensity Normalization of Perfusion MR Studies in Early Alzheimer’s Disease?
por: Lacalle-Aurioles, María, et al.
Publicado: (2013)

The amyloid-β isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's disease
por: PORTELIUS, ERIK, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_sgjaq4m06chavd0055gv6d4km8